4 results
To estimate the bleeding risk with rivaroxaban, compared with ASA, in addition to a singleantiplatelet agent (clopidogrel or ticagrelor), in subjects with a recent ACS .
Primary ObjectivesTo evaluate the effect of MDCO-216 treatment on the change in PAV of a target coronary artery as measured by IVUS imaging following five weekly infusions of MDCO-216 (20 mg/kg) compared with placebo in subjects with a recent ACS.…
The purpose of this study is to evaluate the efficacy, activity, safety, pharmacodynamics and pharmacokinetics of ACP-196 in treating subjects with Mantle Cell Lymphoma (MCL)
The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics and activity of ACP-196 in treating subjects with Waldenström disease.